Chairman, President & CEO of Intra-cellular Therapies Inc (30-Year Financial, Insider Trades) Sharon Mates (insider trades) sold 50,000 shares of ITCI on 11/10/2020 at an average price of $26.34 a share. The total sale was $1.3 million.
Intra-Cellular Therapies Inc is a biopharmaceutical company. It is engaged in discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders. Intra-Cellular Therapies Inc has a market cap of $2.06 billion; its shares were traded at around $25.64 with and P/S ratio of 167.58. GuruFocus has detected 4 severe warning signs with Intra-Cellular Therapies Inc. .
CEO Recent Trades:
- Chairman, President & CEO Sharon Mates sold 50,000 shares of ITCI stock on 11/10/2020 at the average price of $26.34. The price of the stock has decreased by 2.66% since.
- Chairman, President & CEO Sharon Mates sold 50,000 shares of ITCI stock on 11/04/2020 at the average price of $25. The price of the stock has increased by 2.56% since.
Directors and Officers Recent Trades:
- EVP, Chief Commercial Officer Mark Neumann sold 6,792 shares of ITCI stock on 10/16/2020 at the average price of $26.8. The price of the stock has decreased by 4.33% since.
For the complete insider trading history of ITCI, click here
.
